Trading Outlook for Vermillion Inc. Issued by StockPreacher.com

All GlobeNewswire news

DALLAS, Nov. 16, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Vermillion Inc. (Pink Sheets:VRMLQ). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

The investment report on Vermillion Inc. (Pink Sheets:VRMLQ) should be of particular interest to comparable biopharmaceutical/healthcare companies: Abbott Laboratories (NYSE:ABT), Celera Corporation (Nasdaq:CRA) and Bio Rad Laboratories (NYSE:BIO).

The full report is available at: http://www.stockpreacher.com/n/VRMLQ

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher

Vermillion Inc. (VRMLQ) is involved in the discovery, development and commercialization of diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. The Company uses the process of utilizing advanced protein separation methods to identify and resolve variants of specific biomarkers (known as translational proteomics) for developing a procedure to measure a property or concentration of an analyte (known as an assay) and commercializing diagnostic tests. In April 2009, the Company announced that it has filed a voluntary petition for reorganization relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware in Wilmington, Delaware.

Message Board Search for VRMLQ: http://www.boardcentral.com/boards/VRMLQ

In the report, the analyst notes:

"VRMLQ recently announced that the U.S. Patent Office has issued patent number 7,605,003 titled 'Use of biomarkers for detecting ovarian cancer' to the Company for the discovery of biomarkers for ovarian cancer. The patent covers biomarker combinations for both the diagnosis and management of ovarian cancer and covers measurement of the markers by a variety of methods, including mass spectrometry and immunoassay approaches.

"The U.S. Food and Drug Administration (FDA) recently cleared the OVA1(TM) Test, the first blood test that, prior to surgery, can help physicians determine if a woman is at risk for a malignant pelvic mass. OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiological test results fail to indicate malignancy. The test was developed by VRMLQ, a molecular diagnostics company, in cooperation with Quest Diagnostics, the world's leading provider of cancer diagnostics."

To read the entire report visit: http://www.stockpreacher.com/n/VRMLQ

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.

CONTACT:  StockPreacher.com
          Jeff Bishop
          (469)252-3505
          press@beaconequity.com

GlobeNewswire, Inc.2009

Back to News Home

MSN Money

Search MSN Money

Message Boards

Site Status